Evidence map›Paper›PMID 39126575›Full record

ArticleDrug delivery and translational research2025

Carrier-free nanoparticles based on self-assembly of 5-FU and copper-genistein complexes for the combined treatment of hepatocellular carcinoma.

Siwei Chen, Hongwu Huang, Qi Li, Jia Cai, Zhuolin Miao, Peikang Xie, Shengsong Tang, Dongxiu He

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Recent Advances in the Mechanisms and Applications ofMolecules (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Oleanolic acid enhanced the anticancer effect of fluorouracil by regulating Ca2+ levels in hepatocellular carcinoma cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siwei Chen *Miluo Maternity and Child Care Hospital, Yueyang, Hunan Province, China.
Hongwu Huang *Institute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China.
Qi LiInstitute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China.
Jia CaiInstitute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China.
Zhuolin MiaoInstitute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China.
Peikang XieInstitute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China.
Shengsong TangHunan Province Key Laboratory for Antibody-based Drug and Intelligent Delivery Systemy, Huaihua, Hunan, China. tangss_submit@163.com.
Dongxiu HeInstitute of Pharmacy & Pharmacology, University of South China, Hengyang, Hunan, China. 1025165380@qq.com.

Funding

Hunan Provincial Key Laboratory of Robotics and Intelligent Systems 2018TP1044Scientific Research Program of Health Commission of Hunan Province of China No. D202313027885
6 · The paper itself

Abstract

5-Fluorouracil (5-FU) is commonly used as a chemotherapeutic drug for advanced HCC. However, the effectiveness of 5-FU is limited by the emergence of resistance and poor targeting efficiency. Combining 5-FU with natural compounds has shown promise in HCC treatment. In this study, we prepared carrier-free nanoparticles (GEN-Cu-GEN@FUA) containing 5-FU and genistein (GEN) in a synergistic ratio via a green synthesis procedure. The resulting GEN-Cu-GEN@FUA nanoparticles had a spherical or near spherical shape, a dynamic size of 129.3 ± 40.1 nm, and a high drug loading content of approximately 21.40% (5-FU) and 61.48% (GEN). These nanoparticles exhibited approximately 3.6-fold lower IC50 value than 5-FU alone in Bel-7402 cells and resulted in a 3.7-fold greater reduction in tumor weight compared to 5-FU alone in Bel-7402 tumor-bearing BALB/c mice. Importantly, the nanoparticles showed negligible systemic toxicity due to their synergistic effect on cancer cell dysfunction and significant amplification of intracellular glutathione consumption. Our findings suggest that the developed carrier-free nanomedicines offer a highly promising platform for the co-delivery of genistein (GEN) copper(II) complexes and 5-FU, with easy fabrication and great potential for clinical translation in HCC synergistic therapy.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCopperFluorouracilGenisteinLiver NeoplasmsNanoparticlesAnimalsCell Line, TumorCell SurvivalDrug CarriersGlutathioneHumansMiceMice, Inbred BALB CAntineoplastic AgentsCopperDrug CarriersFluorouracilGenisteinGlutathione5-fluorouracilCarrier-free nanoparticleCopper-genistein complexesHepatocellular carcinoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.